Registry on Percutaneous Electrochemotherapy

Launched by CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGICAL SOCIETY OF EUROPE · Feb 23, 2022

Keywords

ClinConnect Summary

The Registry on Percutaneous ElectroChemoTherapy (RESPECT) is a study looking at how effective a treatment called percutaneous electrochemotherapy is for patients with liver cancer. This treatment combines electricity and chemotherapy to help kill cancer cells directly in the liver. The study is currently recruiting participants who are 18 years or older and have either primary liver cancer (cancer that starts in the liver) or secondary liver cancer (cancer that has spread to the liver from another part of the body). To participate, patients need to have a recommendation for treatment from a team of specialists and must be treated with a specific device called the CLINIPORATOR.

If you or someone you know is considering joining this study, you can expect to undergo this innovative treatment under the care of experienced medical professionals. Participants will need to sign a consent form agreeing to take part in the study, and it’s important to note that pregnant individuals cannot participate. This trial aims to gather information that could help improve liver cancer treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • Primary or secondary liver cancer
• • Referral to local ablative treatment by multidisciplinary tumour board and decision to treat with pECT by interventional radiologist in charge
• • Planned treatment with pECT using the CLINIPORATOR
• • Signed informed consent form
• Exclusion Criteria:
• • Pregnancy